Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded May 12, 2025 · Filed May 15, 2025
The CEO of Pasithea Therapeutics sold $792 of Pasithea Therapeutics shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$792
Shares × reported transaction price
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|
| 7 days | +9.3% | −1.3% | +10.6% |
| 30 days | −10.0% | +2.1% | −12.0% |
| 90 days | −16.6% | +9.2% | −25.8% |
| 180 days | −17.5% | +15.7% | −33.2% |
| 365 days | −9.3% | +25.2% | −34.5% |
Past results only. Not a forecast.